Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment
- PMID: 32302703
- PMCID: PMC7194583
- DOI: 10.1016/j.hrthm.2020.04.016
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment
References
-
- Chen C.Y., Wang F.L., Lin C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006;44:173–175. - PubMed
-
- Morgan N.D., Patel S.V., Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol. 2013;19:286–288. - PubMed
-
- de Olano J., Howland M.A., Su M.K., Hoffman R.S., Biary R. Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med. 2019;37 2264.e5–e8. - PubMed
-
- Giudicessi J.R., Noseworthy P.A., Friedman P.A., Ackerman M.J. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc. https://www.elsevier.com/__data/assets/pdf_file/0004/996745/MCP_Possible... Available at: - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
